Agenus: Initial Results From NEOASIS Show BOT/BAL Efficacy In Neoadjuvant Setting Across Multiple MSS And MSI-H Solid Tumors

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting, with outcomes reported in mismatch repair–proficient (pMMR/MSS) and mismatch repair–deficient (dMMR/MSI-H) solid tumors. These findings include the first reported outcomes with BOT/BAL outside colorectal cancer in the neoadjuvant setting.